InVivo licenses CEVEC pharmaceuticals' human CAP-T technology for
production of recombinant proteins
2 October 2009
CEVEC Pharmaceuticals, the developer of a novel human expression
system derived from amniocytes and the contract manufacturer InVivo
BioTech Services GmbH have announced the signing of a strategic license
agreement. This license enables InVivo to offer its customers the
production of their diagnostic and preclinical grade material very fast
and in highest quality, including authentic human glycosylation
patterns, using the novel and proprietary CAP-T transient expression
system.
CAP-T Technology is based on CAP cells, the stable cell line from
CEVEC. The non-tumour origin cells have high expression rates of human
proteins and grow in serum-free suspension culture and
post-translational modifications are human-like. Process times are
reduced by means of large-scale transient transfection.
“After launching our new transient cell in the US market we are
delighted to have now our first customers in Europe not only using our
stable expression system but also working with our new transiently
expressing human cell line. With expression rates outperforming any
other human system on the market, eg HEK 293 freestyle and others, while
offering highest quality human like proteins, we offer our customers a
unique state of the art cell line,” Wolfgang Kintzel, CCO of CEVEC
Pharmaceuticals GmbH states.
Rainer Lichtenberger, CEO of CEVEC, adds. “Because posttranslational
modifications play a significant role for the bioactivity of recombinant
proteins it is of crucial importance to produce proteins with human-like
glycosylation and sialylation.
"With our proprietary human cell lines, CAP for permanent producer
cells for proteins and the novel CAP-T system, only CEVEC is able to
offer a unique range of versatile human cell expression systems to our
customers, from early discovery to protein manufacture. This license
agreement contributes significantly to CEVECs goal becoming the leading
cell line supplier for protein production with human cell expression
systems.”
Bookmark this page